Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 3378 entries
Sorted by: Best Match Show Resources per page
From molecular footprints of disease to new therapeutic interventions in diabetic nephropathy

Stem education interventions

[No authors listed]
GSID: 87c1fQfbhuYJ
T Miyata, M Yamamoto, Y Izuhara - Annals of the New York …, 2005 - Wiley Online Library

Proteins are particularly attractive targets for product analysis, which is used to understand pathology. Protein modifications, such as advanced glycation end products (AGEs), serve as footprints of biochemical processes and also help in the search for novel agents that...

Cite
Miyata, T., Yamamoto, M., & Izuhara, Y. (2005). From molecular footprints of disease to new therapeutic interventions in diabetic nephropathy. Annals of the New York Academy of Sciences, 1043(1), 740-749.
Miyata, Toshio, Makoto Yamamoto, and Yuko Izuhara. "From molecular footprints of disease to new therapeutic interventions in diabetic nephropathy." Annals of the New York Academy of Sciences 1043.1 (2005): 740-749.
Copy Download .nbib Format: MLA
Retraction. Systemic circulatory adjustments to acute hypoxia and reoxygenation in unanesthetized sheep. Role of renin, angiotensin II and catecholamine interactions.

The Journal of clinical investigation

Davidson D, Stalcup SA.
PMID: 3914487
J Clin Invest. 1985 May;75(5):1749.
Free PMC Article

No abstract available.

Cite
Davidson D, Stalcup SA. Retraction. Systemic circulatory adjustments to acute hypoxia and reoxygenation in unanesthetized sheep. Role of renin, angiotensin II and catecholamine interactions. J Clin Invest. 1985;75(5):1749
Davidson, D., & Stalcup, S. A. (1985). Retraction. Systemic circulatory adjustments to acute hypoxia and reoxygenation in unanesthetized sheep. Role of renin, angiotensin II and catecholamine interactions. The Journal of clinical investigation, 75(5), 1749.
Davidson, D, and Stalcup, S A. "Retraction. Systemic circulatory adjustments to acute hypoxia and reoxygenation in unanesthetized sheep. Role of renin, angiotensin II and catecholamine interactions." The Journal of clinical investigation vol. 75,5 (1985): 1749.
Davidson D, Stalcup SA. Retraction. Systemic circulatory adjustments to acute hypoxia and reoxygenation in unanesthetized sheep. Role of renin, angiotensin II and catecholamine interactions. J Clin Invest. 1985 May;75(5):1749. PMID: 3914487; PMCID: PMC425523.
Copy Download .nbib Format: NLM
Suppression of aldosterone synthesis and secretion by ca(2+) channel antagonists.

International journal of endocrinology

Ikeda K, Isaka T, Fujioka K, Manome Y, Tojo K.
PMID: 23097668
Int J Endocrinol. 2012;2012:519467. doi: 10.1155/2012/519467. Epub 2012 Oct 11.

Aldosterone, a specific mineralocorticoid receptor (MR) agonist and a key player in the development of hypertension, is synthesized as a final product of renin-angiotensin-aldosterone system. Hypertension can be generally treated by negating the effects of angiotensin II through the...

Cite
Ikeda K, Isaka T, Fujioka K, et al. Suppression of aldosterone synthesis and secretion by ca(2+) channel antagonists. Int J Endocrinol. 2012;2012:519467doi: 10.1155/2012/519467.
Ikeda, K., Isaka, T., Fujioka, K., Manome, Y., & Tojo, K. (2012). Suppression of aldosterone synthesis and secretion by ca(2+) channel antagonists. International journal of endocrinology, 2012519467. https://doi.org/10.1155/2012/519467
Ikeda, Keiichi, et al. "Suppression of aldosterone synthesis and secretion by ca(2+) channel antagonists." International journal of endocrinology vol. 2012 (2012): 519467. doi: https://doi.org/10.1155/2012/519467
Ikeda K, Isaka T, Fujioka K, Manome Y, Tojo K. Suppression of aldosterone synthesis and secretion by ca(2+) channel antagonists. Int J Endocrinol. 2012;2012:519467. doi: 10.1155/2012/519467. Epub 2012 Oct 11. PMID: 23097668; PMCID: PMC3477571.
Copy Download .nbib Format: NLM
Peptide Vaccines for Hypertension and Diabetes Mellitus.

Vaccines

Nakagami H, Koriyama H, Morishita R.
PMID: 26344893
Vaccines (Basel). 2014 Nov 26;2(4):832-40. doi: 10.3390/vaccines2040832.

Vaccines are commonly used as a preventive medicine for infectious diseases worldwide; however, the trial for an amyloid beta vaccine against Alzheimer's disease will open a new concept in vaccination. In case of therapeutic vaccines for cancer, their targets...

Cite
Nakagami H, Koriyama H, Morishita R. Peptide Vaccines for Hypertension and Diabetes Mellitus. Vaccines (Basel). 2014;2(4):832-40doi: 10.3390/vaccines2040832.
Nakagami, H., Koriyama, H., & Morishita, R. (2014). Peptide Vaccines for Hypertension and Diabetes Mellitus. Vaccines, 2(4), 832-40. https://doi.org/10.3390/vaccines2040832
Nakagami, Hironori, et al. "Peptide Vaccines for Hypertension and Diabetes Mellitus." Vaccines vol. 2,4 (2014): 832-40. doi: https://doi.org/10.3390/vaccines2040832
Nakagami H, Koriyama H, Morishita R. Peptide Vaccines for Hypertension and Diabetes Mellitus. Vaccines (Basel). 2014 Nov 26;2(4):832-40. doi: 10.3390/vaccines2040832. PMID: 26344893; PMCID: PMC4494253.
Copy Download .nbib Format: NLM
Differences Among Angiotensin II Type 1 Receptor Blockers: Characteristics of Candesartan Cilexetil.

Blood pressure

Unger T.
PMID: 28425794
Blood Press. 2000;9:14-18. doi: 10.1080/080370500439164.

Several angiotensin II type 1 (AT 1 ) receptor blockers are now available for the treatment of hypertension. Although the agents in this class all act by blocking the AT 1 -receptor, they differ in their pharmacokinetics and binding...

Cite
Unger T. Differences Among Angiotensin II Type 1 Receptor Blockers: Characteristics of Candesartan Cilexetil. Blood Press. 2000;9:14-18doi: 10.1080/080370500439164.
Unger, T. (2000). Differences Among Angiotensin II Type 1 Receptor Blockers: Characteristics of Candesartan Cilexetil. Blood pressure, 914-18. https://doi.org/10.1080/080370500439164
Unger, Thomas. "Differences Among Angiotensin II Type 1 Receptor Blockers: Characteristics of Candesartan Cilexetil." Blood pressure vol. 9 (2000): 14-18. doi: https://doi.org/10.1080/080370500439164
Unger T. Differences Among Angiotensin II Type 1 Receptor Blockers: Characteristics of Candesartan Cilexetil. Blood Press. 2000;9:14-18. doi: 10.1080/080370500439164. PMID: 28425794.
Copy Download .nbib Format: NLM
Angiotensin II Type 1 Receptor Blockade: a Novel Therapeutic Concept.

Blood pressure

Johnston CI.
PMID: 28425795
Blood Press. 2000;9:9-13. doi: 10.1080/080370500439155.

Angiotensin II type 1 (AT 1 ) receptor blockers, such as candesartan, are attractive alternatives to ACE inhibitors in the treatment of hypertension and cardiovascular disease. Although angiotensin-converting enzyme (ACE) inhibitors are able to suppress the renin-angiotensin system (RAS),...

Cite
Johnston CI. Angiotensin II Type 1 Receptor Blockade: a Novel Therapeutic Concept. Blood Press. 2000;9:9-13doi: 10.1080/080370500439155.
Johnston, C. I. (2000). Angiotensin II Type 1 Receptor Blockade: a Novel Therapeutic Concept. Blood pressure, 99-13. https://doi.org/10.1080/080370500439155
Johnston, Colin I. "Angiotensin II Type 1 Receptor Blockade: a Novel Therapeutic Concept." Blood pressure vol. 9 (2000): 9-13. doi: https://doi.org/10.1080/080370500439155
Johnston CI. Angiotensin II Type 1 Receptor Blockade: a Novel Therapeutic Concept. Blood Press. 2000;9:9-13. doi: 10.1080/080370500439155. PMID: 28425795.
Copy Download .nbib Format: NLM
Candesartan Cilexetil, a Novel Angiotensin II Antagonist, Provides Dose-dependent Antihypertensive Effect with Maintained Tolerability.

Blood pressure

Elmfeldt D, George M, Hübner R, Olofsson B.
PMID: 28425799
Blood Press. 2000;9:54. doi: 10.1080/080370500439272.

Candesartan is a new angiotensin II type 1 (AT 1 ) receptor blocker that binds tightly to and dissociates slowly from the AT 1 -receptor. It is administered as a prodrug, candesartan cilexetil, which is completely converted to the...

Cite
Elmfeldt D, George M, Hübner R, et al. Candesartan Cilexetil, a Novel Angiotensin II Antagonist, Provides Dose-dependent Antihypertensive Effect with Maintained Tolerability. Blood Press. 2000;9:54doi: 10.1080/080370500439272.
Elmfeldt, D., George, M., Hübner, R., & Olofsson, B. (2000). Candesartan Cilexetil, a Novel Angiotensin II Antagonist, Provides Dose-dependent Antihypertensive Effect with Maintained Tolerability. Blood pressure, 954. https://doi.org/10.1080/080370500439272
Elmfeldt, D, et al. "Candesartan Cilexetil, a Novel Angiotensin II Antagonist, Provides Dose-dependent Antihypertensive Effect with Maintained Tolerability." Blood pressure vol. 9 (2000): 54. doi: https://doi.org/10.1080/080370500439272
Elmfeldt D, George M, Hübner R, Olofsson B. Candesartan Cilexetil, a Novel Angiotensin II Antagonist, Provides Dose-dependent Antihypertensive Effect with Maintained Tolerability. Blood Press. 2000;9:54. doi: 10.1080/080370500439272. PMID: 28425799.
Copy Download .nbib Format: NLM
Candesartan Cilexetil, a Novel Angiotensin II Type 1 (AT1) Receptor Blocker, Reduces Microalbuminuria in Patients with Type II Diabetes Mellitus and Mild Hypertension.

Blood pressure

Trenkwalder P, Dahl K, Lehtovirta M, Mulder H.
PMID: 28425802
Blood Press. 2000;9:57. doi: 10.1080/080370500439308.

Microalbuminuria is a predictor of nephropathy in patients with type I or type II diabetes mellitus, and interventions that decrease albuminuria are likely to postpone the development of severe renal impairment. Suppression of the renin-angiotensin system by angiotensin-converting enzyme...

Cite
Trenkwalder P, Dahl K, Lehtovirta M, et al. Candesartan Cilexetil, a Novel Angiotensin II Type 1 (AT1) Receptor Blocker, Reduces Microalbuminuria in Patients with Type II Diabetes Mellitus and Mild Hypertension. Blood Press. 2000;9:57doi: 10.1080/080370500439308.
Trenkwalder, P., Dahl, K., Lehtovirta, M., & Mulder, H. (2000). Candesartan Cilexetil, a Novel Angiotensin II Type 1 (AT1) Receptor Blocker, Reduces Microalbuminuria in Patients with Type II Diabetes Mellitus and Mild Hypertension. Blood pressure, 957. https://doi.org/10.1080/080370500439308
Trenkwalder, P, et al. "Candesartan Cilexetil, a Novel Angiotensin II Type 1 (AT1) Receptor Blocker, Reduces Microalbuminuria in Patients with Type II Diabetes Mellitus and Mild Hypertension." Blood pressure vol. 9 (2000): 57. doi: https://doi.org/10.1080/080370500439308
Trenkwalder P, Dahl K, Lehtovirta M, Mulder H. Candesartan Cilexetil, a Novel Angiotensin II Type 1 (AT1) Receptor Blocker, Reduces Microalbuminuria in Patients with Type II Diabetes Mellitus and Mild Hypertension. Blood Press. 2000;9:57. doi: 10.1080/080370500439308. PMID: 28425802.
Copy Download .nbib Format: NLM
Preserving Target-organ Function with Candesartan Cilexetil in Patients with Hypertension.

Blood pressure

Zannad F.
PMID: 28425806
Blood Press. 2000;9:36-39. doi: 10.1080/080370500439218.

Epidemiological evidence suggests that reducing blood pressure alone in hypertensive patients delays the onset of cardiovascular events without necessarily preventing the progression of chronic target-organ disease, such as end-stage renal failure and heart failure. Successful clinical management of hypertensive...

Cite
Zannad F. Preserving Target-organ Function with Candesartan Cilexetil in Patients with Hypertension. Blood Press. 2000;9:36-39doi: 10.1080/080370500439218.
Zannad, F. (2000). Preserving Target-organ Function with Candesartan Cilexetil in Patients with Hypertension. Blood pressure, 936-39. https://doi.org/10.1080/080370500439218
Zannad, Faiez. "Preserving Target-organ Function with Candesartan Cilexetil in Patients with Hypertension." Blood pressure vol. 9 (2000): 36-39. doi: https://doi.org/10.1080/080370500439218
Zannad F. Preserving Target-organ Function with Candesartan Cilexetil in Patients with Hypertension. Blood Press. 2000;9:36-39. doi: 10.1080/080370500439218. PMID: 28425806.
Copy Download .nbib Format: NLM
A Combination of Candesartan Cilexetil/hydrochlorothiazide (HCTZ), 8/12.5 mg, has a Similar Antihypertensive Efficacy and is Better Tolerated than Lisinopril/HCTZ, 10/12.5 mg.

Blood pressure

T McINNES G, Istad H, Keinänen-Kiukaanniemi S, VAN Mierlo HFCM.
PMID: 28425809
Blood Press. 2000;9:61. doi: 10.1080/080370500439344.

Monotherapy with an antihypertensive agent is likely to achieve a desirable lowering of blood pressure in about 50% of patients. The remaining proportion of patients are likely to be only partially responsive or unresponsive, even if appropriate dose adjustments...

Cite
T McINNES G, Istad H, Keinänen-Kiukaanniemi S, et al. A Combination of Candesartan Cilexetil/hydrochlorothiazide (HCTZ), 8/12.5 mg, has a Similar Antihypertensive Efficacy and is Better Tolerated than Lisinopril/HCTZ, 10/12.5 mg. Blood Press. 2000;9:61doi: 10.1080/080370500439344.
T McINNES, G., Istad, H., Keinänen-Kiukaanniemi, S., & VAN Mierlo, H. F. C. M. (2000). A Combination of Candesartan Cilexetil/hydrochlorothiazide (HCTZ), 8/12.5 mg, has a Similar Antihypertensive Efficacy and is Better Tolerated than Lisinopril/HCTZ, 10/12.5 mg. Blood pressure, 961. https://doi.org/10.1080/080370500439344
T McINNES, G, et al. "A Combination of Candesartan Cilexetil/hydrochlorothiazide (HCTZ), 8/12.5 mg, has a Similar Antihypertensive Efficacy and is Better Tolerated than Lisinopril/HCTZ, 10/12.5 mg." Blood pressure vol. 9 (2000): 61. doi: https://doi.org/10.1080/080370500439344
T McINNES G, Istad H, Keinänen-Kiukaanniemi S, VAN Mierlo HFCM. A Combination of Candesartan Cilexetil/hydrochlorothiazide (HCTZ), 8/12.5 mg, has a Similar Antihypertensive Efficacy and is Better Tolerated than Lisinopril/HCTZ, 10/12.5 mg. Blood Press. 2000;9:61. doi: 10.1080/080370500439344. PMID: 28425809.
Copy Download .nbib Format: NLM
Candesartan, an Insurmountable Antagonist of Angiotensin II-mediated Contractile Effects in Isolated Vascular Preparations: Comparison with Irbesartan, Losartan and its Active Metabolite (EXP-3174).

Blood pressure

Morsing U Brandt-Eliasson L Renberg T Abrahamsson P.
PMID: 28425810
Blood Press. 2000;9:50-51. doi: 10.1080/080370500439245.

Candesartan is a new angiotensin II type 1 (AT 1 ) receptor blocker that produces more effective 24-h blood pressure lowering than losartan in hypertensive patients. In in vitro tissue preparations, candesartan displays insurmountable antagonism of the responses to...

Cite
Morsing U Brandt-Eliasson L Renberg T Abrahamsson P. Candesartan, an Insurmountable Antagonist of Angiotensin II-mediated Contractile Effects in Isolated Vascular Preparations: Comparison with Irbesartan, Losartan and its Active Metabolite (EXP-3174). Blood Press. 2000;9:50-51doi: 10.1080/080370500439245.
Morsing U Brandt-Eliasson L Renberg T Abrahamsson, P. (2000). Candesartan, an Insurmountable Antagonist of Angiotensin II-mediated Contractile Effects in Isolated Vascular Preparations: Comparison with Irbesartan, Losartan and its Active Metabolite (EXP-3174). Blood pressure, 950-51. https://doi.org/10.1080/080370500439245
Morsing U Brandt-Eliasson L Renberg T Abrahamsson, P. "Candesartan, an Insurmountable Antagonist of Angiotensin II-mediated Contractile Effects in Isolated Vascular Preparations: Comparison with Irbesartan, Losartan and its Active Metabolite (EXP-3174)." Blood pressure vol. 9 (2000): 50-51. doi: https://doi.org/10.1080/080370500439245
Morsing U Brandt-Eliasson L Renberg T Abrahamsson P. Candesartan, an Insurmountable Antagonist of Angiotensin II-mediated Contractile Effects in Isolated Vascular Preparations: Comparison with Irbesartan, Losartan and its Active Metabolite (EXP-3174). Blood Press. 2000;9:50-51. doi: 10.1080/080370500439245. PMID: 28425810.
Copy Download .nbib Format: NLM
Gastrodin Inhibits Store-Operated Ca.

Frontiers in pharmacology

Zheng C, Lo CY, Meng Z, Li Z, Zhong M, Zhang P, Lu J, Yang Z, Yan F, Zhang Y, Huang Y, Yao X.
PMID: 28487655
Front Pharmacol. 2017 Apr 25;8:222. doi: 10.3389/fphar.2017.00222. eCollection 2017.

Cardiac hypertrophy is a major risk factor for heart failure, which are among the leading causes of human death. Gastrodin is a small molecule that has been used clinically to treat neurological and vascular diseases for many years without...

Cite
Zheng C, Lo CY, Meng Z, et al. Gastrodin Inhibits Store-Operated Ca. Front Pharmacol. 2017;8:222doi: 10.3389/fphar.2017.00222.
Zheng, C., Lo, C. Y., Meng, Z., Li, Z., Zhong, M., Zhang, P., Lu, J., Yang, Z., Yan, F., Zhang, Y., Huang, Y., & Yao, X. (2017). Gastrodin Inhibits Store-Operated Ca. Frontiers in pharmacology, 8222. https://doi.org/10.3389/fphar.2017.00222
Zheng, Changbo, et al. "Gastrodin Inhibits Store-Operated Ca." Frontiers in pharmacology vol. 8 (2017): 222. doi: https://doi.org/10.3389/fphar.2017.00222
Zheng C, Lo CY, Meng Z, Li Z, Zhong M, Zhang P, Lu J, Yang Z, Yan F, Zhang Y, Huang Y, Yao X. Gastrodin Inhibits Store-Operated Ca. Front Pharmacol. 2017 Apr 25;8:222. doi: 10.3389/fphar.2017.00222. eCollection 2017. PMID: 28487655; PMCID: PMC5404510.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 3378 entries